Recent Updates
Recently added Catalysts
CLDX

Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference

Key Takeaway: HAMPTON, N.J., June 06, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Tibor Keler, Ph.D., Co-founder, Executive Vice President and Chief Scientific Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will p

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+77%
120-day peak, hindsight
Typical move
6.2%
average across 6 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
barzolvolimab
Phase 3 · Chronic Inducible Urticaria

Full Press Release Details

HAMPTON, N.J., June 06, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Tibor Keler, Ph.D., Co-founder, Executive Vice President and Chief Scientific Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fireside chat at the Jefferies 2017 Global Healthcare Conference on June 8, 2017 at 11:00 a.m. EDT in New York.
The live webcast will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for seven days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.
Last updated: Jun 6, 2017